Cargando…

Regulatory B cells in autoimmune rheumatic diseases

BACKGROUND: Regulatory B cells (regulatory B cells, Breg cells) in recent years have been shown to be important immunoregulatory factors. AIM: To review the role of Breg cells in autoimmune rheumatic diseases. METHODS: This descriptional review was carried out after research on PubMed using the keyw...

Descripción completa

Detalles Bibliográficos
Autor principal: Sakkas, Lazaros I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046031/
https://www.ncbi.nlm.nih.gov/pubmed/32185261
http://dx.doi.org/10.31138/mjr.28.2.75
_version_ 1783501892578443264
author Sakkas, Lazaros I.
author_facet Sakkas, Lazaros I.
author_sort Sakkas, Lazaros I.
collection PubMed
description BACKGROUND: Regulatory B cells (regulatory B cells, Breg cells) in recent years have been shown to be important immunoregulatory factors. AIM: To review the role of Breg cells in autoimmune rheumatic diseases. METHODS: This descriptional review was carried out after research on PubMed using the keywords “Bregs and rheumatoid arthritis”, “systemic lupus erythematosus”, “Sjögren’s syndrome”, “systemic sclerosis”, “vasculitis”, and “dermatomyositis”. RESULTS: Breg cells have an inhibitory effect on pro-inflammatory Th1 and Th17 cells and prevent the development of autoimmune diseases. Breg cells mediate their effects through interleukin-10 (IL-10, IL-10+Breg cells), but recently other Breg cells have been recognized that mediate their effects through IL-35 (IL-35+Breg cells), or through transforming growth factor-β (TGFβ, TGFβ+Breg cells). In experimental models of autoimmune diseases, Breg cells are decreased, and when expanded ex vivo and re-infused back into animals, they ameliorate disease. In humans, IL-10+Breg cells are decreased in active autoimmune diseases, such as rheumatoid arthritis, ANCA-associated vasculitis, and systemic sclerosis, and may increase to normal levels in disease remission. CONCLUSIONS: The deficiency of IL-10+Breg cells during active autoimmune rheumatic disease suggests that Breg cells may be used as biomarkers and be a possible therapeutic target in these diseases.
format Online
Article
Text
id pubmed-7046031
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-70460312020-03-17 Regulatory B cells in autoimmune rheumatic diseases Sakkas, Lazaros I. Mediterr J Rheumatol Review BACKGROUND: Regulatory B cells (regulatory B cells, Breg cells) in recent years have been shown to be important immunoregulatory factors. AIM: To review the role of Breg cells in autoimmune rheumatic diseases. METHODS: This descriptional review was carried out after research on PubMed using the keywords “Bregs and rheumatoid arthritis”, “systemic lupus erythematosus”, “Sjögren’s syndrome”, “systemic sclerosis”, “vasculitis”, and “dermatomyositis”. RESULTS: Breg cells have an inhibitory effect on pro-inflammatory Th1 and Th17 cells and prevent the development of autoimmune diseases. Breg cells mediate their effects through interleukin-10 (IL-10, IL-10+Breg cells), but recently other Breg cells have been recognized that mediate their effects through IL-35 (IL-35+Breg cells), or through transforming growth factor-β (TGFβ, TGFβ+Breg cells). In experimental models of autoimmune diseases, Breg cells are decreased, and when expanded ex vivo and re-infused back into animals, they ameliorate disease. In humans, IL-10+Breg cells are decreased in active autoimmune diseases, such as rheumatoid arthritis, ANCA-associated vasculitis, and systemic sclerosis, and may increase to normal levels in disease remission. CONCLUSIONS: The deficiency of IL-10+Breg cells during active autoimmune rheumatic disease suggests that Breg cells may be used as biomarkers and be a possible therapeutic target in these diseases. The Mediterranean Journal of Rheumatology (MJR) 2017-06-27 /pmc/articles/PMC7046031/ /pubmed/32185261 http://dx.doi.org/10.31138/mjr.28.2.75 Text en © 2017 The Mediterranean Journal of Rheumatology (MJR) http://creativecommons.org/licenses/by/4.0/ This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Review
Sakkas, Lazaros I.
Regulatory B cells in autoimmune rheumatic diseases
title Regulatory B cells in autoimmune rheumatic diseases
title_full Regulatory B cells in autoimmune rheumatic diseases
title_fullStr Regulatory B cells in autoimmune rheumatic diseases
title_full_unstemmed Regulatory B cells in autoimmune rheumatic diseases
title_short Regulatory B cells in autoimmune rheumatic diseases
title_sort regulatory b cells in autoimmune rheumatic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046031/
https://www.ncbi.nlm.nih.gov/pubmed/32185261
http://dx.doi.org/10.31138/mjr.28.2.75
work_keys_str_mv AT sakkaslazarosi regulatorybcellsinautoimmunerheumaticdiseases